Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...

Me is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the ...

Key regulatory milestones and financial updates position Sangamo Therapeutics Inc (SGMO) for potential growth despite funding ...

Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and ...

It also comes after a pledge by the company to plough savings from a cost-reduction drive back into its pipeline. The three platform deals are long-term bets, but broaden Genentech’s drug ...

and is coming up to a two-decade anniversary at the Roche/Genentech group. She also took control of the company during Hardy’s recent sabbatical, a longstanding policy at the biotech unit that ...

Genentech, a member of the Roche (RHHBY), announced that it will present more than 40 abstracts across nine blood disorders at the 66th American Society of Hematology, or ASH, annual meeting and ...

primarily due to their Genentech agreement, leading to a net income of $10.7 million compared to a loss in the previous year. Strategic developments include the submission of an IND application for a ...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported business highlights and third quarter 2024 financial results. "This is ...

13, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Valo Health today announced that industry leader ... Research & Development and Head of Boston Roche Innovation ...

Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening ...